News

NANBIOSIS U25 Showcases Innovative MRI Research at the 41st ESMRMB Annual Scientific Meeting in Marseille

NANBIOSIS U25 presented innovative MRI research on CAM cancer models at the ESMRMB 2025 meeting in Marseille, highlighting advances in preclinical imaging.

Marseille, October 2025 — Unit 25 of NANBIOSIS – the Biomedical Applications of Nuclear Magnetic Resonance platform at the Universitat Autònoma de Barcelona (UAB) – participated in the 41st Annual Scientific Meeting of the European Society for Magnetic Resonance in Biology and Medicine (ESMRMB), held in Marseille from 9–11 October. The event gathered leading experts in magnetic resonance imaging (MRI), spectroscopy, and biomedical imaging to discuss advances shaping the future of the field.

Unit 25 presented new research on longitudinal MRI in emerging preclinical cancer models, reinforcing its longstanding expertise in advanced NMR-based biomedical applications.

Presentation of Cutting-Edge Research on Novel Preclinical Models

The work, presented on site by Dr. Ana Paula Candiota, Scientific Director of Unit 25, was carried out in collaboration with Dr. Silvia Lope-Piedrafita, Scientific Coordinator of the Unit, and the Josep Carreras Leukemia Research Institute.

The study, accepted as a late abstract, is entitled: “Longitudinal MRI for tumor evaluation in two immunocompetent chicken chorioallantoic membrane (CAM) cancer xenograft models: A Registered Report.”

The research highlights the potential of the CAM model as a novel immunocompetent platform for cancer studies. Despite inherent challenges—such as model size and magnetic susceptibility effects—the preliminary MRI results show strong promise. The study demonstrates that longitudinal MR approaches can effectively monitor tumour progression in CAM xenografts, opening the door to alternative, cost-effective, and ethically favourable preclinical cancer models.

About NANBIOSIS Unit 25: Biomedical Applications of Nuclear Magnetic Resonance

Unit 25 is inegrated within the Servei de Ressonància Magnètica Nuclear (SeRMN), which provides Nuclear Magnetic Resonance instrumentation and technical support. The Unit, lead by Dr. Ana Paula Candiota, has a recognized record of excellence in applying NMR to biomedical research. This service provides access to state-of-the-art equipment and capabilities, such as 10 spectrometers operating between 5.8 and 14.1 Tesla, including a 7T Bruker BioSpec MRI scanner dedicated to preclinical research.

A unique integrated environment

Unit 25 offers unparalleled access to in vivo, ex vivo, and in vitro NMR systems in a single location, along with molecular imaging tools using polarization.

This configuration enables the validation of in vivo molecular imaging results through complementary in vitro analyses, significantly strengthening translational research outcomes.

Strengthening NANBIOSIS Visibility in the European MRI Community

The presence of Unit 25 at ESMRMB 2025 underscores NANBIOSIS’ commitment to supporting cutting-edge biomedical imaging research and fostering high-impact collaborations internationally. The presentation in Marseille further consolidated the Unit’s visibility within the European MRI community and highlighted the relevance of novel preclinical models in advancing cancer research.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

NANBIOSIS Unit 6 highlights cutting-edge biointeraction techniques at BIOMED 2025 Workshop

NANBIOSIS U6 contributed to BIOMED 2025 at ICMAB with a talk on ITC and SPR, showcasing advanced tools for biomolecular interaction analysis.

Barcelona, October 2025 — last 22 October 2025, the Institute of Materials Science of Barcelona (ICMAB–CSIC) hosted the BIOMED 2025: Workshop on Experimental Techniques for Biomedicine, bringing together early-career researchers to explore pivotal biomedical characterization methods.

As a key contributor, NANBIOSIS Unit 6, the Soft Materials Service at ICMAB-CSIC, showcased its expertise through a technical talk delivered by David Piña Muñoz — “Unraveling and Quantifying Molecular Biointeractions through ITC and SPR.” This presentation underscored the Unit’s advanced instrumentation capabilities in isothermal titration calorimetry (ITC) and surface plasmon resonance (SPR).

Unpacking ITC and SPR capabilities

During his talk, David Piña explained how ITC provides thermodynamic profiles of molecular interactions by directly measuring heat changes upon binding, offering insights into binding affinity, stoichiometry, enthalpy, and entropy. Meanwhile, SPR enables real-time, label-free monitoring of biomolecular binding kinetics — capturing association and dissociation rates with high sensitivity. Together, these complementary techniques empower researchers to comprehensively characterize biomolecular interactions.

These services are part of the broader Soft Materials platform at Unit 6, which integrates a suite of advanced characterization tools tailored for soft and biomaterials research.

About NANBIOSIS Unit 6: Soft Materials Service

NANBIOSIS Unit 6 is based at ICMAB–CSIC in Barcelona, coordinated by Prof. Nora Ventosa, who also leads the NANOMOL group. The Unit specializes in the development, processing, and characterization of nano- and microstructured molecular soft materials with therapeutic or biomedical relevance.

A standout capability of Unit 6 is its compressed-fluid biomaterials processing platform, including the proprietary DELOS-SUSP one-step method using compressed CO₂. This technology enables the scalable production of particulate biomaterials with controlled size, internal structure, and supramolecular organization — from milliliters to liters. The Unit is also ISO 9001 certified, ensuring high-quality standards across its operations.

Impact of the BIOMED 2025 Workshop

The BIOMED 2025 workshop was designed to support early-stage biomedical researchers, offering a hybrid format (in-person and online) that covered a spectrum of techniques — from cell culture basics to advanced biophysical analysis. By delivering a session on ITC and SPR, NANBIOSIS Unit 6 not only contributed scientific knowledge but also reinforced its role as a core technology provider for the biomedical community.

Participants benefited from expert-led discussions, hands-on insights into characterization tools, and networking opportunities with leading researchers in materials science and biomedicine.

Further Information & Contacts

• Soft Materials Service, ICMAB-CSIC: Visit the SOFT ICMAB website for more details on instrumentation and services.
• NANBIOSIS Unit 6: Learn about U6 – Soft Materials Service, its research lines, and technological capabilities.
• Contact: You can reach the SOFT Materials Service at ICMAB via servicios.soft@icmab.es.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

Young researchers from CIBERES and CIBER-BBN connect in El Escorial to advance biomedical research and micro-nano technologies

Young researchers from CIBERES and CIBER-BBN met in El Escorial, where NANBIOSIS presented its organ-on-chip project “Chips R Us”.

Madrid, November 2025 — More than sixty young researchers from the CIBERES and CIBER-BBN networks gathered at the Euroforum center for the 2025 CIBERES–CIBER-BBN Young Researchers Conference (Jornadas de Personal Investigador Joven). The event fostered collaboration between early-career scientists in biomedical engineering, nanomedicine, and respiratory research, while highlighting the role of advanced micro- and nanotechnologies in healthcare innovation.

A platform for collaboration and emerging research

Organized by CIBERES (CIBER area of Respiratory Diseases) in collaboration with CIBER-BBN (CIBER area of Bioengineering, Biomaterials, and Nanomedicine), the two-day conference promoted knowledge exchange and interdisciplinary cooperation.

The program included talks on international funding opportunities, citizen engagement in biomedical research, and multiple sessions dedicated to oral and poster communications covering fields such as nanoparticles for targeted therapy, respiratory infection diagnostics, sleep apnea detection, and biomimetic organ-on-chip models.

NANBIOSIS presents “Chips R Us”: advancing organ-on-chip technology

A highlight of the event was the presentation of “Chips R Us”, a project coordinated by NANBIOSIS, Spain’s distributed research infrastructure for biomaterials and nanomedicine. The project was introduced by Gabriel Alfranca, Communication Manager of NANBIOSIS and coordinator of the project, alongside Denise Marrero (CIBER-BBN), a researcher in the group led by Dr. Rosa Villa and Dr. Xavier Illa at the Microelectronic Institute of Barcelona (IMB-CNM, CSIC), where NANBIOSIS Unit 8 – Micro-Nano Technologies is located.

Their presentation showcased the project’s goal of developing organ-on-chip platforms — particularly lung-on-chip models — to improve disease diagnostics and enable tailored therapeutic strategies. These innovative microdevices are fabricated using the clean-room facilities of IMB-CNM, Spain’s largest installation for micro- and nanofabrication processes.

NANBIOSIS Unit 8: a cornerstone for biomedical microfabrication

NANBIOSIS Unit 8 is very close collaboration with the MICRONANOFABS network, a Singular Scientific and Technical Infrastructure (ICTS), same category as NANBIOSIS. The Unit offers expertise in CVD graphene fabrication, photolithography, metallization, and flexible biocompatible substrates such as polyimide and parylene — key technologies for creating biomedical implants, neuroprostheses, and organ-on-chip devices.

By integrating microelectronics and biotechnology, Unit 8 enables researchers from both academia and industry to translate nanotechnology into functional biomedical solutions. The Unit’s support for Chips R Us exemplifies how NANBIOSIS infrastructures accelerate innovation across disciplines.

Empowering young scientists in translational research

Throughout the sessions, early-career scientists from CIBERES and CIBER-BBN demonstrated their expertise in cutting-edge topics such as molecular biosensing, nanodiagnostics, respiratory disease modeling, and advanced biomaterials. The conference also featured networking sessions like “Posters & Beers,” where participants exchanged ideas in an informal setting.

In closing remarks, the organizers emphasized the importance of interdisciplinary collaboration and the role of national research infrastructures like NANBIOSIS in supporting translational and applied research. Events such as these not only strengthen cooperation among research centers but also provide young investigators with the tools and connections to shape the future of biomedical innovation.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

NANBIOSIS Showcases Biosensor Innovation as Sponsor of EBS2025 in Tarragona

NANBIOSIS sponsored EBS2025 in Tarragona, showcasing the advances of Units 2 & 29 in antibodies and oligonucleotides for next-gen biosensors.

Tarragona, October 2025 — NANBIOSIS proudly participated as an official sponsor of the 5th European Biosensor Symposium (EBS2025), held from 26 to 29 October 2025 in Tarragona. The international event, chaired by Prof. Dr. M. Pilar Marco (IQAC-CSIC / CIBER-BBN and Scientific Director of Unit 2 of NANBIOSIS), brought together hundreds of researchers, engineers and industry leaders to discuss the latest advances in biosensors, nanotechnology, microfluidics, and diagnostic devices.

Through its Unit 2 and Unit 29, NANBIOSIS highlighted its key role in supporting cutting-edge biosensor research and development — from custom antibody generation to oligonucleotide synthesis — providing essential technological capabilities for the next generation of diagnostic and monitoring tools.

NANBIOSIS: Driving Innovation in Biosensor Research

As a national Singular Scientific and Technical Infrastructure (ICTS), NANBIOSIS provides open access to advanced facilities and expert support in biomedicine, nanomedicine, biomaterials and biosensors.
Its participation in EBS2025 reinforces the infrastructure’s mission to bridge academic research and industrial innovation, helping translate discoveries into practical applications that benefit health, environment, and society.

Unit 2: Custom Antibody Service (CAbS-Nb4D-CSIC)

Represented at the symposium by members of the Nanobiotechnology for Diagnostics (Nb4D) group at IQAC-CSIC, Unit 2 showcased its extensive experience in the design, production and characterization of custom immunoreagents.

The Custom Antibody Service (CAbS) provides comprehensive solutions for hapten synthesis, monoclonal and polyclonal antibody generation, and antibody conjugation with enzymes, fluorophores or nanoparticles.
Its ISO 9001:2015-certified processes ensure high-quality reagents for biosensing applications across sectors such as medical diagnostics, food safety, environmental monitoring, and biomarker detection.

During EBS2025, the Nb4D group, which also chaired the conference, presented advances in immunosensor design and analytical performance optimization, highlighting how antibody engineering can enhance biosensor sensitivity and selectivity.

Unit 29: Oligonucleotide Synthesis Platform (OSP)

Also based at IQAC-CSIC, Unit 29 – the Oligonucleotide Synthesis Platform (OSP) – plays a pivotal role in developing nucleic-acid-based biosensors. The unit specializes in the synthesis, purification and characterization of modified oligonucleotides, including DNA and RNA derivatives conjugated with lipids, peptides or carbohydrates.

At EBS2025, Unit 29 representatives engaged with researchers developing aptamer-based biosensors and nucleic acid diagnostics, exploring opportunities for collaboration in sequence modification, bioconjugation and sensor surface functionalization.

These capabilities align closely with current trends in biosensing and nanotechnology, where hybrid bio-nano systems are key to creating more sensitive, specific, and portable diagnostic devices.

Strengthening Collaboration in the European Biosensor Community

EBS2025 offered NANBIOSIS a valuable opportunity to connect with international experts, startups, and industry partners. The symposium’s scientific sessions showcased breakthroughs in AI-enhanced biosensors, organ-on-chip models, nanomaterial-based detection, and wearable diagnostic technologies.

Through its sponsorship and active participation, NANBIOSIS reaffirmed its role as a strategic partner in European biosensor research, offering comprehensive services that cover the entire innovation pipeline – from biomolecule design to device functionalization and validation.

About the European Biosensor Symposium 2025

The 5th European Biosensor Symposium (EBS2025) took place in the Tarragona Exhibition and Congress Center, gathering leading scientists from academia and industry. The event was organized by IQAC-CSIC and CIBER-BBN, under the leadership of Prof. M. Pilar Marco, with support from sponsors such as NANBIOSIS, Universitat Rovira i Virgili (URV), and Reial Acadèmia de Farmàcia de Catalunya.

The symposium addressed emerging trends in biosensing technologies, micro- and nanofabrication, artificial intelligence for diagnostics, and organ-on-chip platforms – reflecting the multidisciplinary nature of modern biosensor research.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

NANBIOSIS Strengthens Internal Collaboration at 2025 Networking Event in Cáceres

NANBIOSIS held its 2025 networking event in Cáceres to boost collaboration among Units in biomaterials, nanomedicine, and biomedical research.

Cáceres, October 2025 — From 22 to 24 October 2025, the Singular Scientific and Technical Infrastructure (ICTS) NANBIOSIS held its annual internal networking event at the Centro de Cirugía de Mínima Invasión Jesús Usón (CCMIJU) in Cáceres, Spain. The event brought together Unit coordinators, researchers, and technical staff from across Spain to foster collaboration, share scientific progress, and explore new opportunities for joint projects in biomedical research, nanomedicine, and biotechnology.

A meeting to boost collaboration across NANBIOSIS Units

The three-day event was designed to enhance synergy among all the Units that make up NANBIOSIS, a distributed infrastructure offering cutting-edge services for biomaterials, nanomaterials, bioimaging, preclinical validation, and high-performance computing.

The meeting opened on 22 October with a welcome address by the Secretary General for Science of the Junta de Extremadura, who highlighted the strategic importance of research infrastructures like NANBIOSIS for innovation in health technologies. This was followed by an introduction to the initiative “Cutting Edge Biomedical Solutions”, reinforcing the mission of NANBIOSIS to support advanced biomedical development.

That afternoon, participants presented their work grouped under three scientific programmes:

• Programme 1: Production of Biomolecules (Units 1 to 3 and 29)
• Programme 2: Production of Biomaterials and Nanomaterials (Units 6 to 10)
• Programme 5: High-Performance Computing (Unit 27)

The day concluded with a networking session encouraging informal exchanges and inter-Unit dialogue, in the context of the outstanding facilities of CCMIJU, one of the three nodes that form NANBIOSIS.

Guided Tour and Technical Presentations at CCMIJU

On 23 October, participants took part in a guided tour of CCMIJU, visiting the centre’s advanced research facilities in preclinical studies, imaging technologies, and tissue engineering.

After a short coffee break, the morning continued with presentations from Programme 3: Preclinical Validation – Characterisation of Tissues, Biomaterials and Surfaces (Units 12 to 19, and 30). Finally, the last programme was explained that same day in the afternoon, with Programme 4: Preclinical Validation – Bioimaging (Units 20 to 26, and 28).

Similarly to the previous day, throughout the day networking sessions facilitated direct interaction between teams, helping identify new collaboration opportunities across scientific programmes.

To close the technical sessions, participants joined “The NANBIOSIS Contest”, an interactive Kahoot-style quiz promoting engagement and friendly competition. In the evening, a guided cultural visit of Cáceres allowed attendees to explore the historic city’s UNESCO World Heritage old town.

Strengthening the NANBIOSIS Network

The final day, 24 October, saw participants returning to Madrid, concluding an event marked by enthusiasm, collaboration, and a strong sense of community across the infrastructure.

This internal networking event successfully:

• Reinforced communication and coordination among NANBIOSIS Units.
• Promoted awareness of each Unit’s services, equipment, and expertise.
• Laid the groundwork for new interdisciplinary collaborations and new CEBS.
• Highlighted the role of NANBIOSIS as a national and international reference in biomedical innovation and nanotechnology.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

NANBIOSIS at BIOSPAIN 2025: Strengthening public-private bridges for translational nanomedicine

NANBIOSIS joins BIOSPAIN 2025 with ISCIII and CIBER, boosting biotech partnerships and showcasing early HTA and ARISTOS innovations.

Barcelona, October 2025 — Last week NANBIOSIS took part in BIOSPAIN 2025 (Fira de Barcelona Montjuïc), joining forces at the ISCIII / CIBER stand to showcase our facilities and to deepen collaborations with industry partners, users and strategic allies. Over three intensive days the NANBIOSIS and CIBER representatives held multiple meetings with potential private partners and technology users to accelerate translation of nanomedicine and biomedical technologies.

Record edition: numbers that matter

BIOSPAIN 2025 closed as the largest edition to date: more than 2,400 attendees from 1,065 organisations across 34 countries, 140 investors representing 76 investment entities, ~250 exhibitors, and over 4,500 one-to-one meetings, reinforcing BIOSPAIN as Spain’s (and one of Europe’s) main partnering platform for biotechnology and life sciences. Organisers also announced Bilbao as the host city for BIOSPAIN 2026 (September 29–October 1, 2026).

NANBIOSIS contributions and leadership at the congress

NANBIOSIS participation combined exhibition, partnering and scientific leadership:

• We staffed the joint ISCIII–CIBER stand, connecting NANBIOSIS Units and services with industry delegates interested in diagnostics, drug delivery, advanced therapies and computational/biomanufacturing resources. These meetings generated promising follow-ups for collaborative projects and user requests.
• Prof. Pilar Marco (Research Professor, CSIC; Head of CIBER-BBN; and Scientific Director of NANBIOSIS Unit 2 (Custom Antibody Service, CAbS) moderated the roundtable “Early Health Technology Assessment: Designing the Roadmap for Successful Medical Innovation Translation.” The session emphasised the strategic value of embedding HTA early in the research-to-market pipeline to improve clinical relevance, cost-effectiveness, stakeholder alignment and the success of technology transfer.

ARISTOS Fellows presenting translational projects (NANBIOSIS connections)

At the 1st ARISTOS Entrepreneurs Dissemination Day (an event of the ARISTOS Postdoctoral Programme co-funded by the EU Marie Skłodowska-Curie COFUND and CIBER), several ARISTOS fellows linked to CIBER-BBN and working with NANBIOSIS Units presented projects aimed at clinical translation and industry uptake. These presentations fostered direct dialogue with private-sector experts on exploitation and secondment opportunities. Confirmed speakers included: Erika Pineda Ramírez (NanoGlue: glue-nanoparticles for immunotherapy) working in the group of Prof. Ramón Martínez Máñez, Director of NANBIOSIS and Scientific Director of Unit 26 (NMR applications); Sofía Romagnoli (BRUHealth: ECGi + multiscale cardiac modelling for Brugada syndrome), working in the group of Prof. Pablo Laguna, Scientific Director of Unit 27 (High Performance Computing), Dr Lilianne Beola Guibert (next-generation living organoids for high-throughput clinical testing) working in the group of Prof. Jesús M. de la Fuente; and Dr Salim Çeriğ (OLEO-CardioSafe: stem-cell strategy to prevent chemotherapy cardiotoxicity) working in the group of Prof. Ángel Raya. ARISTOS is funded under Marie Skłodowska-Curie grant No 101081334.

Why early HTA and infrastructures like NANBIOSIS matter

The BIOSPAIN programme under the motto “Global crossroads, local vibes” foregrounded three strategic pillars — health, investment and sustainability — and highlighted how convergence (biotech + engineering + digitalisation) and multidisciplinary talent accelerate industrial transformation. NANBIOSIS’s open-access platforms (characterised by advanced instrumentation, standardised workflows and regulatory/quality expertise) are designed to help researchers and SMEs implement early HTA-informed development and provide the evidence and technical readiness levels required by investors, regulators and hospitals. The combination of early economic, clinical and organisational assessment with robust preclinical services reduces the risk of late-stage failure and speeds up market access.

Moving forward: follow-ups and next steps

As BIOSPAIN transitions to an annual format and prepares for Bilbao 2026, NANBIOSIS will continue to:

• pursue partnerships initiated at BIOSPAIN 2025 (industry secondments, collaborative R&D, service contracts);
• support ARISTOS and other postdoctoral talent in accelerating commercial pathways for their projects; and
• promote early HTA integration alongside preclinical/characterisation services to improve translation outcomes.

If you are an industry partner or researcher who met NANBIOSIS at BIOSPAIN 2025 and would like to continue the conversation, please contact our communications or business development team via: info@nanbiosis.es

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

Danish Students Visit NANBIOSIS U28 NanoImaging at IBIMA-BIONAND to Discover Biomedical Imaging Technologies

Danish students visit NANBIOSIS Unit 28 at IBIMA-BIONAND to explore cutting-edge nanoimaging technologies driving innovation in biomedical research.

Málaga, October 2025 — A delegation of students from Denmark visited the NanoImaging Unit (U28), part of NANBIOSIS ICTS and embedded within IBIMA Plataforma BIONAND, for a hands-on introduction to its scientific and technical capabilities. This international exchange allowed them to engage with the facility’s staff, explore cutting-edge instrumentation, and see how nanoimaging plays a pivotal role in biomedical research and innovation in health.

During the visit, the students had the opportunity to observe demonstrations of imaging modalities, ask questions about preclinical and molecular imaging workflows, and gain insights into how these technologies accelerate research in nanomedicine. The exchange underscores the commitment of NANBIOSIS and IBIMA to nurture scientific vocations, facilitate knowledge transfer, and strengthen cross-European collaboration in health research.

About NANBIOSIS Unit 28

The NanoImaging Unit (U28) is hosted by IBIMA Plataforma BIONAND, at the Andalusian Centre for Nanomedicine and Biotechnology (BIONAND) in Málaga. It is accredited as a node of NANBIOSIS ICTS and offers advanced imaging services to internal and external users.

Core Capabilities & Departments

U28 is structured into four main technological areas, each supporting a specialized domain of biomedical nanoimaging:

• Small Animal Multimodal Imaging – includes MRI, in vivo bioluminescence and fluorescence imaging, and micro-CT for non-invasive preclinical studies.
• Magnetic Resonance (NMR) – equipped with a 400 MHz spectrometer for routine work and a 600 MHz instrument capable of HR-MAS (high-resolution magic angle spinning) and advanced in vitro analysis. Also includes a TD-NMR analyzer for relaxivity measurements.
• Electron Microscopy – offers TEM, Cryo-TEM, electron tomography, high-resolution SEM, and environmental SEM, with advanced sample preparation (e.g. cryo-immobilization) for biological and nanomedicine applications.
• Advanced Fluorescence / Optical Microscopy – includes confocal microscopy, multiphoton microscopy, super-resolution imaging, fluorescence imaging, and high content screening. Integration with other modalities supports comprehensive multimodal studies.

These capabilities enable U28 to support molecular imaging, structural and functional studies, characterization of nano-compounds, and preclinical evaluations. In addition, the NanoImaging Unit is closely linked to complementary facilities within BIONAND, including the Cell Culture Unit, Chemical Unit, Animal House (supporting rodents and zebrafish), and the Histology Unit (which provides advanced sectioning, including for hard materials).

As a recognized ICTS node, U28 contributes to the Spanish map of singular scientific and technical infrastructures, enabling high-level access to imaging technologies for national and international users. The Unit underpins translational nanomedicine research in Spain and Europe by providing cutting-edge instrumentation and expertise.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

Hands-on Course on 3D Bioprinting for Pharmaceutical and Biomedical Applications

Hands-on 3D Bioprinting course at UPV/EHU on Oct 23–24, 2025, covers pharma and biomedical applications with expert-led demos and training.

Vitoria, September, 2025 — The University of the Basque Country (UPV/EHU) will host a Hands-on Short Course on 3D Bioprinting for Pharmaceutical and Biomedical Applications on October 23–24, 2025, at the Lascaray Ikergunea Research Center in Vitoria-Gasteiz. This training program is designed to provide participants with both fundamental knowledge and practical skills in 3D bioprinting, a rapidly emerging technology with applications in drug development, regenerative medicine, and biomedical research.

Program highlights

Over two days, the course will combine lectures and demonstrations by international experts from academia and industry. The program includes:

• Introduction to 3D bioprinting.
• Biomaterials, cells, and bioink formulation.
• Cell imaging in 3D microenvironments.
• Extrusion-based bioprinting and its applications.
• Bioprinting for pharmaceutical sciences.
• Bioprinting in regenerative medicine.
• Two live bioprinting demonstration sessions.

The course concludes with an assessment and evaluation session to consolidate learning.

International faculty

The course brings together a prestigious group of instructors, including:

• Dr. Murugan Ramalingam (UPV/EHU) – Course Director
• Prof. José Luis Pedraz (UPV/EHU) – Course Director
• Dr. Denis Scaini, Dr. Sandra Ruiz Alonso, and Dr. Jon Zarate (UPV/EHU),
• Nicola Paccione (Tecnalia)
• Dr. Andrew Shevchuk (Imperial College London, UK)
• Dr. Thomas Webster (InnoShapes Inc., USA)
• Dr. Yu Shrike Zhang (Harvard University, USA)
• Dr. Sean Murphy (Wake Forest University, USA)
• Dr. Deepak Kalaskar (UCL, UK)

NANBIOSIS Unit 10: Drug Formulation

This initiative is also aligned with the work of NANBIOSIS Unit 10: Drug Formulation, led by Prof. José Luis Pedraz, who serves as one of the course directors. Unit 10 provides advanced services in drug delivery systems, nanomedicine, and bioink development for pharmaceutical and biomedical applications. Through its cutting-edge infrastructure, the Unit supports both academic research and industrial projects, fostering innovation in personalized medicine and advanced therapies.

Practical details

• Dates: October 23–24, 2025
• Venue: Lascaray Ikergunea Research Center, UPV/EHU Campus de Álava, Vitoria-Gasteiz, Spain
• Fee: €84.96
• Registration deadline: October 20, 2025
• Register here: Official link for registration

This short course offers a unique opportunity to gain hands-on training in 3D bioprinting technologies, learn from global leaders, and explore future collaborations between academia and industry.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them: